MSICS Pharma, an Israeli startup developing medical-grade psilocybin production technology, has raised $3.6 million to advance clinical trials for treatment-resistant depression, PTSD, and obsessive-compulsive disorder. The company was founded by brothers Roei Zerahia (CEO) and Omer Zerahia (CBO), who previously led Canndoc, a medical cannabis company now traded on Nasdaq that generates over 250 million NIS in annual revenue.
MSICS holds an official license from Israel’s Ministry of Health for GMP manufacturing of psilocybin for medical purposes—making it the sole company in Israel and Europe with such authorization. The company’s flagship product, MSX-06, is integrated into medical protocols for complex clinical indications. Omer Zerahia explained the motivation: “Based on our trials, psilocybin shows strong potential in treating depression, obsessive-compulsive disorder, and other conditions that currently lack effective solutions. In depression, most of our studies have demonstrated very strong results, with up to 70% full remission.”
The funding comes following an Executive Order signed by U.S. President Donald Trump directing the FDA to grant “Fast Track” status to psychedelic therapies and expanding the “Right to Try” act for veterans and trauma survivors. The order has triggered stock surges among leading public psychedelic companies including Compass Pathways, ATAI Life Sciences, and Definium Therapeutics.
MSICS is conducting Phase II clinical trials for treatment-resistant depression and obsessive-compulsive disorder, combining standardized GMP psilocybin with proven psychotherapeutic protocols. The company is set to begin a large-scale, multi-center clinical trial for PTSD in collaboration with four leading Israeli hospitals. The capital will support expanded production capacity, clinical trial acceleration, and preparation for commercial registration and global supply. The company employs approximately 12 people in Israel.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.calcalistech.com/ctechnews/article/byoweavrbg